New research by The Worldcom Public Relations Group has ranked pharmaceutical companies according to their usage of digital channels – with Bayer, Pfizer and Boehringer Ingelheim coming out on top.

We found that useful information held by the manufacturing companies is not currently shared in a sufficiently transparent ... Roche Diagnostics, Boehringer Ingelheim, and Lilly through ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer will leverage ExpressionEdits' Genetic Syntax Engine which generates optimized introns to increase protein expression.

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. The phase 3 program missed both primary ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

ExpressionEdits' Genetic Syntax Engine platform is designed to enhance gene expression within gene therapies by restoring introns.

Boehringer Ingelheim India has signed a Memorandum of Understanding (MoU) with Hyderabad-based EMRI Green Health Services a GVK enterprise, the operator of the Government-funded 108 National Emergency ...